{"protocolSection": {"identificationModule": {"nctId": "NCT01914757", "orgStudyIdInfo": {"id": "D3250C00018"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist", "officialTitle": "A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist (CALIMA)"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-08"}, "primaryCompletionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-07-31", "studyFirstSubmitQcDate": "2013-07-31", "studyFirstPostDateStruct": {"date": "2013-08-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-08", "resultsFirstSubmitQcDate": "2016-11-30", "resultsFirstPostDateStruct": {"date": "2017-01-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-30", "lastUpdatePostDateStruct": {"date": "2017-01-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2508, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab 30 mg q.4 weeks", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Benralizumab 30 mg q.8 weeks", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 8 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered subcutaneously", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab subcutaneously on study week 0 until study week 52 inclusive.", "armGroupLabels": ["Benralizumab 30 mg q.4 weeks", "Benralizumab 30 mg q.8 weeks"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo subcutaneously on study week 0 until study week 52 inclusive.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}], "secondaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Change in Asthma Rescue Medication Use", "description": "Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Home Lung Function Assessments Based on PEF", "description": "Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \\[PEF\\])", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Proportion of Nights With Awakening Due to Asthma", "description": "Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Number of Patients With >=1 Asthma Exacerbation", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Time to First Asthma Exacerbation", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations", "description": "Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)", "timeFrame": "Immediately following the first administration of study drug through Study Week 56."}, {"measure": "Pharmacokinetics of Benralizumab", "description": "Mean PK Concentration at each visit", "timeFrame": "Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60"}, {"measure": "Immunogenicity of Benralizumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.", "timeFrame": "Pre-treatment until end of follow-up"}, {"measure": "Extent of Exposure", "description": "Extent of exposure is defined as the duration of treatment in days", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Mean Change From Baseline to Week 56 in AQLQ(S)+12", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Change From Baseline to Week 56 in EQ-5D-5L VAS", "description": "EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Mean Work Productivity Loss Due to Asthma", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Mean Productivity Loss Due to Asthma in Classroom", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Number of Participants That Utilized Health Care Resources", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}, {"measure": "Patient and Clinician Assessment of Response to Treatment", "description": "CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.", "timeFrame": "Immediately following the first administration of study drug through Study Week 56"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1\n3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (\\>250\u00b5g fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1.\n4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 \u03bcg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, the mid-strength approved maintenance dose in the local country will meet this ICS criterion.\n\nExclusion criteria:\n\n1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)\n2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n   * Affect the safety of the patient throughout the study\n   * Influence the findings of the studies or their interpretations\n   * Impede the patient's ability to complete the entire duration of study\n3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period\n4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mark Fitzgerald, MD, PhD, Professor of Medicine", "affiliation": "The Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver Canada", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Andalusia", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 31.30809, "lon": -86.48245}}, {"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Flagstaff", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 35.19807, "lon": -111.65127}}, {"facility": "Research Site", "city": "Glendale", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Research Site", "city": "Alhambra", "state": "California", "country": "United States", "geoPoint": {"lat": 34.09529, "lon": -118.12701}}, {"facility": "Research Site", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Research Site", "city": "Beverly Hills", "state": "California", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "Research Site", "city": "Garden Grove", "state": "California", "country": "United States", "geoPoint": {"lat": 33.77391, "lon": -117.94145}}, {"facility": "Research Site", "city": "Lakewood", "state": "California", "country": "United States", "geoPoint": {"lat": 33.85363, "lon": -118.13396}}, {"facility": "Research Site", "city": "North Hollywood", "state": "California", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Research Site", "city": "Northridge", "state": "California", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Palmdale", "state": "California", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Research Site", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Research Site", "city": "Redondo Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.84918, "lon": -118.38841}}, {"facility": "Research Site", "city": "Rolling Hills Estate", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Thousand Oaks", "state": "California", "country": "United States", "geoPoint": {"lat": 34.17056, "lon": -118.83759}}, {"facility": "Research Site", "city": "Upland", "state": "California", "country": "United States", "geoPoint": {"lat": 34.09751, "lon": -117.64839}}, {"facility": "Research Site", "city": "Ventura", "state": "California", "country": "United States", "geoPoint": {"lat": 34.27834, "lon": -119.29317}}, {"facility": "Research Site", "city": "Walnut Creek", "state": "California", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Research Site", "city": "Westminister", "state": "California", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Woodland", "state": "California", "country": "United States", "geoPoint": {"lat": 38.67852, "lon": -121.7733}}, {"facility": "Research Site", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Wheat Ridge", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Research Site", "city": "Celebration", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.32529, "lon": -81.53313}}, {"facility": "Research Site", "city": "Fort Lauderdale", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Homestead", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.46872, "lon": -80.47756}}, {"facility": "Research Site", "city": "Jacksonville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Research Site", "city": "Lehigh Acres", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.62535, "lon": -81.6248}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Ocala", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Ormond Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.28581, "lon": -81.05589}}, {"facility": "Research Site", "city": "Virginia Gardens", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.81038, "lon": -80.30227}}, {"facility": "Research Site", "city": "Gainesville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Research Site", "city": "Smyrna", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.88399, "lon": -84.51438}}, {"facility": "Research Site", "city": "Eagle", "state": "Idaho", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "Research Site", "city": "Shiloh", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 38.56144, "lon": -89.89732}}, {"facility": "Research Site", "city": "Lenexa", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 38.95362, "lon": -94.73357}}, {"facility": "Research Site", "city": "Fort Mitchell", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Research Site", "city": "Covington", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.47549, "lon": -90.10042}}, {"facility": "Research Site", "city": "Bangor", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Research Site", "city": "Farmington Hills", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.48531, "lon": -83.37716}}, {"facility": "Research Site", "city": "Flint", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"facility": "Research Site", "city": "Traverse City", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 44.76306, "lon": -85.62063}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "St Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Las Vagas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Union", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.6976, "lon": -74.2632}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Wilmington", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Columbus", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Research Site", "city": "Dayton", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Research Site", "city": "Middleburg Heights", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Corvallis", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.56457, "lon": -123.26204}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Jefferson Hills", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.29118, "lon": -79.93199}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Indian Land", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 35.00067, "lon": -80.87914}}, {"facility": "Research Site", "city": "Rapid City", "state": "South Dakota", "country": "United States", "geoPoint": {"lat": 44.08054, "lon": -103.23101}}, {"facility": "Research Site", "city": "Knoxville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Research Site", "city": "Arlington", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Research Site", "city": "Austin", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Research Site", "city": "Boerne", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Midvale", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.61106, "lon": -111.89994}}, {"facility": "Research Site", "city": "Murray", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Research Site", "city": "Fairfax", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Research Site", "city": "Falls Church", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Milwaukee", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad Aut\u00f3noma de Bs. As.", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Concepci\u00f3n del Uruguay", "country": "Argentina", "geoPoint": {"lat": -32.48249, "lon": -58.23722}}, {"facility": "Research Site", "city": "Corrientes", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "Florida", "country": "Argentina"}, {"facility": "Research Site", "city": "Godoy Cruz", "country": "Argentina", "geoPoint": {"lat": -32.92863, "lon": -68.8351}}, {"facility": "Research Site", "city": "La Plata", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Research Site", "city": "Mar del Plata", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Research Site", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Ranelagh", "country": "Argentina", "geoPoint": {"lat": -34.79591, "lon": -58.1977}}, {"facility": "Research Site", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "San Miguel de Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Moncton", "state": "New Brunswick", "country": "Canada", "geoPoint": {"lat": 46.09454, "lon": -64.7965}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "St Charles Borromee", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Concepcion", "country": "Chile", "geoPoint": {"lat": -36.82699, "lon": -73.04977}}, {"facility": "Research Site", "city": "Quillota", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Research Site", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Talcahuano", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Research Site", "city": "Valparaiso", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Research Site", "city": "Vi\u00f1a del Mar", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Research Site", "city": "Aschaffenburg", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Research Site", "city": "Bamberg", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Bonn", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Research Site", "city": "Frankfurt/Main", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Geesthacht", "country": "Germany", "geoPoint": {"lat": 53.43575, "lon": 10.3779}}, {"facility": "Research Site", "city": "Gelsenkirchen", "country": "Germany", "geoPoint": {"lat": 51.50508, "lon": 7.09655}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Herford", "country": "Germany", "geoPoint": {"lat": 52.11457, "lon": 8.67343}}, {"facility": "Research Site", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "M\u00fcnchen", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Research Site", "city": "Neu-Isenburg", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "Research Site", "city": "Rostock", "country": "Germany", "geoPoint": {"lat": 54.0887, "lon": 12.14049}}, {"facility": "Research Site", "city": "R\u00fcdersdorf", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Research Site", "city": "Witten", "country": "Germany", "geoPoint": {"lat": 51.44362, "lon": 7.35258}}, {"facility": "Research Site", "city": "Asahi-shi", "country": "Japan", "geoPoint": {"lat": 35.71667, "lon": 140.65}}, {"facility": "Research Site", "city": "Chiyoda-ku", "country": "Japan"}, {"facility": "Research Site", "city": "Chuo-ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Fukuoka-shi", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Himeji-shi", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Research Site", "city": "Hiroshima-shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Research Site", "city": "Itabashi-ku", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Kagoshima-shi", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kishiwada-shi", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Research Site", "city": "Kobe-shi", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Kokubunji-shi", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Research Site", "city": "Matsue-shi", "country": "Japan", "geoPoint": {"lat": 35.48333, "lon": 133.05}}, {"facility": "Research Site", "city": "Minato-ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Research Site", "city": "Mizunami-shi", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 137.25}}, {"facility": "Research Site", "city": "Niigata-shi", "country": "Japan", "geoPoint": {"lat": 37.88637, "lon": 139.00589}}, {"facility": "Research Site", "city": "Obihiro-shi", "country": "Japan", "geoPoint": {"lat": 42.91722, "lon": 143.20444}}, {"facility": "Research Site", "city": "Oita-shi", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 131.6}}, {"facility": "Research Site", "city": "Ota-shi", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Research Site", "city": "Sagamihara-shi", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Research Site", "city": "Sakai-shi", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 135.46667}}, {"facility": "Research Site", "city": "Sakaide-shi", "country": "Japan"}, {"facility": "Research Site", "city": "Sapporo-shi", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Sendai-shi", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Research Site", "city": "Setagaya-ku", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Research Site", "city": "Shibuya-ku", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Research Site", "city": "Shinagawa-ku", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Research Site", "city": "Sumida-ku", "country": "Japan"}, {"facility": "Research Site", "city": "Takamatsu-shi", "country": "Japan", "geoPoint": {"lat": 34.33333, "lon": 134.05}}, {"facility": "Research Site", "city": "Toshima-ku", "country": "Japan"}, {"facility": "Research Site", "city": "Tsukubo-gun", "country": "Japan"}, {"facility": "Research Site", "city": "Yokohama-shi", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Iloilo City", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Research Site", "city": "Lipa City", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "Research Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Research Site", "city": "Aleksandr\u00f3w \u0141\u00f3dzki", "country": "Poland", "geoPoint": {"lat": 51.81965, "lon": 19.30384}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Bielsko Biala", "country": "Poland", "geoPoint": {"lat": 49.82245, "lon": 19.04686}}, {"facility": "Research Site", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Bystra \u015al\u0105ska", "country": "Poland"}, {"facility": "Research Site", "city": "Gda\u0144sk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Gorz\u00f3w Wlkp", "country": "Poland"}, {"facility": "Research Site", "city": "Karczew", "country": "Poland", "geoPoint": {"lat": 52.07655, "lon": 21.24962}}, {"facility": "Research Site", "city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Research Site", "city": "Koszalin", "country": "Poland", "geoPoint": {"lat": 54.19438, "lon": 16.17222}}, {"facility": "Research Site", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lubin", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Research Site", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Ostr\u00f3w Wielkopolski", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Research Site", "city": "Pozna\u0144", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Ruda Slaska", "country": "Poland", "geoPoint": {"lat": 50.2584, "lon": 18.85632}}, {"facility": "Research Site", "city": "Rzesz\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "Research Site", "city": "Skierniewice", "country": "Poland", "geoPoint": {"lat": 51.95485, "lon": 20.15837}}, {"facility": "Research Site", "city": "Szczecin", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Toru\u0144", "country": "Poland", "geoPoint": {"lat": 53.01375, "lon": 18.59814}}, {"facility": "Research Site", "city": "Trzebnica", "country": "Poland", "geoPoint": {"lat": 51.31076, "lon": 17.06331}}, {"facility": "Research Site", "city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Wielu\u0144", "country": "Poland", "geoPoint": {"lat": 51.22097, "lon": 18.56964}}, {"facility": "Research Site", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Zabrze", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "\u0141\u0119czna", "country": "Poland", "geoPoint": {"lat": 51.30121, "lon": 22.88135}}, {"facility": "Research Site", "city": "\u017bnin", "country": "Poland", "geoPoint": {"lat": 52.84958, "lon": 17.71992}}, {"facility": "Research Site", "city": "Bragadiru", "country": "Romania", "geoPoint": {"lat": 44.37111, "lon": 25.9775}}, {"facility": "Research Site", "city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Research Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Research Site", "city": "Constanta", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"facility": "Research Site", "city": "Deva", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Research Site", "city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Research Site", "city": "Timisoara", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Research Site", "city": "Goteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Lule\u00e5", "country": "Sweden", "geoPoint": {"lat": 65.58415, "lon": 22.15465}}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Chernivtsi", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Research Site", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Lutsk", "country": "Ukraine", "geoPoint": {"lat": 50.75932, "lon": 25.34244}}, {"facility": "Research Site", "city": "Mykolayiv", "country": "Ukraine", "geoPoint": {"lat": 46.96591, "lon": 31.9974}}, {"facility": "Research Site", "city": "Uzhgorod", "country": "Ukraine", "geoPoint": {"lat": 48.61667, "lon": 22.3}}, {"facility": "Research Site", "city": "Vinnytsia", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Research Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Research Site", "city": "Zaporizhzhia", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Zaporozhye", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}]}, "referencesModule": {"references": [{"pmid": "35287231", "type": "DERIVED", "citation": "Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14."}, {"pmid": "32334141", "type": "DERIVED", "citation": "Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22."}, {"pmid": "31836949", "type": "DERIVED", "citation": "Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14."}, {"pmid": "31626906", "type": "DERIVED", "citation": "Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15."}, {"pmid": "30802500", "type": "DERIVED", "citation": "Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23."}, {"pmid": "30139780", "type": "DERIVED", "citation": "Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct."}, {"pmid": "30077185", "type": "DERIVED", "citation": "DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4."}, {"pmid": "29409951", "type": "DERIVED", "citation": "Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1."}, {"pmid": "29128192", "type": "DERIVED", "citation": "Ohta K, Adachi M, Tohda Y, Kamei T, Kato M, Mark Fitzgerald J, Takanuma M, Kakuno T, Imai N, Wu Y, Aurivillius M, Goldman M. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018 Apr;67(2):266-272. doi: 10.1016/j.alit.2017.10.004. Epub 2017 Nov 8."}, {"pmid": "27609406", "type": "DERIVED", "citation": "FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkstrom V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5."}], "seeAlsoLinks": [{"label": "D3250C00018CSP3redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1823&filename=d3250c00018_Revised_CSP_CALIMA..pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "2505 participants signed informed consent, 2181 entered screening/run-in period, 1306 participants were randomised to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 1306 patients randomised, all (100.0%) received treatment with study drug.", "groups": [{"id": "FG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "FG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "FG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "425"}, {"groupId": "FG001", "numSubjects": "441"}, {"groupId": "FG002", "numSubjects": "440"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "389"}, {"groupId": "FG001", "numSubjects": "390"}, {"groupId": "FG002", "numSubjects": "402"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "51"}, {"groupId": "FG002", "numSubjects": "38"}]}], "dropWithdraws": [{"type": "Severe non-compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Study specific withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Eligibility criteria not fulfilled", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Other reasons", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "BG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "BG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "425"}, {"groupId": "BG001", "value": "441"}, {"groupId": "BG002", "value": "440"}, {"groupId": "BG003", "value": "1306"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.0", "spread": "13.6"}, {"groupId": "BG001", "value": "49", "spread": "14.3"}, {"groupId": "BG002", "value": "48.8", "spread": "15.1"}, {"groupId": "BG003", "value": "49.2", "spread": "14.3"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "270"}, {"groupId": "BG001", "value": "273"}, {"groupId": "BG002", "value": "264"}, {"groupId": "BG003", "value": "807"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "168"}, {"groupId": "BG002", "value": "176"}, {"groupId": "BG003", "value": "499"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "lowerLimit": "0.48", "upperLimit": "0.74"}, {"groupId": "OG001", "value": "0.66", "lowerLimit": "0.54", "upperLimit": "0.82"}, {"groupId": "OG002", "value": "0.93", "lowerLimit": "0.77", "upperLimit": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Negative Binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate Ratio", "paramValue": "0.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.49", "ciUpperLimit": "0.85"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "Negative Binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.", "paramType": "Rate Ratio", "paramValue": "0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.54", "ciUpperLimit": "0.95"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL, High-dose ICS.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.78", "lowerLimit": "0.59", "upperLimit": "1.02"}, {"groupId": "OG001", "value": "0.73", "lowerLimit": "0.55", "upperLimit": "0.95"}, {"groupId": "OG002", "value": "1.21", "lowerLimit": "0.96", "upperLimit": "1.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.015", "statisticalMethod": "Negative Binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate Ratio", "paramValue": "0.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "0.92"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Negative Binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.", "paramType": "Rate Ratio", "paramValue": "0.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.42", "ciUpperLimit": "0.86"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "216"}, {"groupId": "OG001", "value": "211"}, {"groupId": "OG002", "value": "221"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.34", "spread": "0.469"}, {"groupId": "OG001", "value": "0.332", "spread": "0.518"}, {"groupId": "OG002", "value": "0.206", "spread": "0.471"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.125", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.037", "ciUpperLimit": "0.213"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.01", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.116", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.028", "ciUpperLimit": "0.204"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "98"}, {"groupId": "OG002", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.221", "spread": "0.441"}, {"groupId": "OG001", "value": "0.164", "spread": "0.358"}, {"groupId": "OG002", "value": "0.135", "spread": "0.437"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.268", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.064", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.049", "ciUpperLimit": "0.176"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.786", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.127", "ciUpperLimit": "0.096"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "185"}, {"groupId": "OG002", "value": "187"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "spread": "1.23"}, {"groupId": "OG001", "value": "-1.4", "spread": "1.17"}, {"groupId": "OG002", "value": "-1.2", "spread": "1.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.224", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.32", "ciUpperLimit": "0.07"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.43", "ciUpperLimit": "-0.04"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "1.14"}, {"groupId": "OG001", "value": "-0.95", "spread": "1.13"}, {"groupId": "OG002", "value": "-0.88", "spread": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.287", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "0.13"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.966", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.28", "ciUpperLimit": "0.29"}]}, {"type": "SECONDARY", "title": "Change in Asthma Rescue Medication Use", "description": "Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs per day", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "185"}, {"groupId": "OG002", "value": "187"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "3.64"}, {"groupId": "OG001", "value": "-2.92", "spread": "3.60"}, {"groupId": "OG002", "value": "-2.65", "spread": "9.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.603", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma rescue medication use, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "0.99"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.209", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline Asthma medication use, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.29", "ciUpperLimit": "0.28"}]}, {"type": "SECONDARY", "title": "Home Lung Function Assessments Based on PEF", "description": "Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \\[PEF\\])", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"title": "Change at Week 56, Morning (n=194, 193, 197)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.745", "spread": "78.534"}, {"groupId": "OG001", "value": "43.375", "spread": "91.865"}, {"groupId": "OG002", "value": "23.961", "spread": "71.509"}]}]}, {"title": "Change at Week 56, Evening (n=194, 192, 197)", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.142", "spread": "75.489"}, {"groupId": "OG001", "value": "39.270", "spread": "89.772"}, {"groupId": "OG002", "value": "15.448", "spread": "78.341"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Morning PEF Change from Baseline to Week 56", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.029", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "15.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.59", "ciUpperLimit": "30.12"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Morning PEF Change from Baseline to Week 56", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.037", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "15.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.9", "ciUpperLimit": "29.64"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Evening PEF Change from Baseline to Week 56", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "17.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.07", "ciUpperLimit": "32"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Evening PEF Change from Baseline to Week 56", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "21.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.65", "ciUpperLimit": "35.79"}]}, {"type": "SECONDARY", "title": "Proportion of Nights With Awakening Due to Asthma", "description": "Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion of nights", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "196"}, {"groupId": "OG001", "value": "198"}, {"groupId": "OG002", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.373", "spread": "0.388"}, {"groupId": "OG001", "value": "-0.431", "spread": "0.4"}, {"groupId": "OG002", "value": "-0.372", "spread": "0.405"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.03"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.146", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.01"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "185"}, {"groupId": "OG002", "value": "197"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.34", "spread": "1.13"}, {"groupId": "OG001", "value": "-1.49", "spread": "1.13"}, {"groupId": "OG002", "value": "-1.21", "spread": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.043", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "-0.01"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "-0.07"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "1.16"}, {"groupId": "OG001", "value": "-1.06", "spread": "1.02"}, {"groupId": "OG002", "value": "-0.83", "spread": "1.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.078", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.51", "ciUpperLimit": "0.03"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.449", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.16"}]}, {"type": "SECONDARY", "title": "Number of Patients With >=1 Asthma Exacerbation", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "95"}, {"groupId": "OG002", "value": "126"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Proportion of patients with \\>=1 asthma exacerbation", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region, number of exacerbations in the previous year, use of OCS", "paramType": "Odds Ratio (OR)", "paramValue": "0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.31", "ciUpperLimit": "0.69"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Proportion of patients with \\>=1 asthma exacerbation", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.023", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region, number of exacerbations in the previous year, use of OCS", "paramType": "Odds Ratio (OR)", "paramValue": "0.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "0.95"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "95"}, {"groupId": "OG002", "value": "126"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Time to first Exacerbation", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "statisticalComment": "Model includes treatment, region, number of exacerbations in the previous year, use of OCS", "paramType": "Hazard Ratio (HR)", "paramValue": "0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "0.80"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Time to first asthma exacerbation", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "statisticalMethod": "Regression, Cox", "statisticalComment": "Model includes treatment, region, number of exacerbations in the previous year, use of OCS", "paramType": "Hazard Ratio (HR)", "paramValue": "0.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.55", "ciUpperLimit": "0.95"}]}, {"type": "SECONDARY", "title": "Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations", "description": "Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 56.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "lowerLimit": "0.02", "upperLimit": "0.06"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "0.03", "upperLimit": "0.08"}, {"groupId": "OG002", "value": "0.04", "lowerLimit": "0.02", "upperLimit": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.837", "statisticalMethod": "negative binomial", "statisticalComment": "Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS", "paramType": "Rate Ratio", "paramValue": "0.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.48", "ciUpperLimit": "1.82"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.538", "statisticalMethod": "negative binomial", "statisticalComment": "Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS", "paramType": "Rate Ratio", "paramValue": "1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "2.35"}]}, {"type": "SECONDARY", "title": "Pharmacokinetics of Benralizumab", "description": "Mean PK Concentration at each visit", "populationDescription": "PK analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "435"}, {"groupId": "OG001", "value": "424"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline (n=435, 419)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}]}]}, {"title": "Week 4 (n=430, 416)", "categories": [{"measurements": [{"groupId": "OG000", "value": "650.04", "spread": "154.61"}, {"groupId": "OG001", "value": "703.16", "spread": "89.48"}]}]}, {"title": "Week 8 (n=414, 395)", "categories": [{"measurements": [{"groupId": "OG000", "value": "894.86", "spread": "148.91"}, {"groupId": "OG001", "value": "939.45", "spread": "98.99"}]}]}, {"title": "Week 16 (n=390, 378)", "categories": [{"measurements": [{"groupId": "OG000", "value": "936.43", "spread": "247.46"}, {"groupId": "OG001", "value": "252.54", "spread": "274.74"}]}]}, {"title": "Week 24 (n=388, 361)", "categories": [{"measurements": [{"groupId": "OG000", "value": "827.09", "spread": "370.64"}, {"groupId": "OG001", "value": "188.99", "spread": "308.38"}]}]}, {"title": "Week 32 (n=345, 323)", "categories": [{"measurements": [{"groupId": "OG000", "value": "823.21", "spread": "362.43"}, {"groupId": "OG001", "value": "166.53", "spread": "289.34"}]}]}, {"title": "Week 40 (n=370, 338)", "categories": [{"measurements": [{"groupId": "OG000", "value": "859.69", "spread": "364.28"}, {"groupId": "OG001", "value": "172.28", "spread": "298.6"}]}]}, {"title": "Week 48 (n=355, 337)", "categories": [{"measurements": [{"groupId": "OG000", "value": "888.09", "spread": "333.98"}, {"groupId": "OG001", "value": "186.5", "spread": "290.28"}]}]}, {"title": "Week 56 (n=358, 344)", "categories": [{"measurements": [{"groupId": "OG000", "value": "763.98", "spread": "309.18"}, {"groupId": "OG001", "value": "173.41", "spread": "235.86"}]}]}, {"title": "Week 60 (n=49, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.63", "spread": "1782.96"}, {"groupId": "OG001", "value": "18.63", "spread": "756.47"}]}]}]}, {"type": "SECONDARY", "title": "Immunogenicity of Benralizumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Pre-treatment until end of follow-up", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "438"}, {"groupId": "OG001", "value": "427"}, {"groupId": "OG002", "value": "440"}]}], "classes": [{"title": "Positive at any visit (n=438, 427, 440)", "categories": [{"measurements": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Base- and Post-baseline Postive (n=431, 414, 430)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Only post-baseline positive (n=431, 420, 436)", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Persistently positive (n=431, 420, 436)", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Transient positive (n=431, 420, 436)", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Only baseline positive (n=438, 421, 434)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Extent of Exposure", "description": "Extent of exposure is defined as the duration of treatment in days", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "438"}, {"groupId": "OG001", "value": "428"}, {"groupId": "OG002", "value": "440"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "344.14", "spread": "73.129"}, {"groupId": "OG001", "value": "331.64", "spread": "88.839"}, {"groupId": "OG002", "value": "336.69", "spread": "82.148"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 56 in AQLQ(S)+12", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "180"}, {"groupId": "OG002", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.44", "spread": "1.15"}, {"groupId": "OG001", "value": "1.61", "spread": "1.24"}, {"groupId": "OG002", "value": "1.32", "spread": "1.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.119", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.37"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "0.45"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 56 in EQ-5D-5L VAS", "description": "EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "183"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.8", "spread": "21.52"}, {"groupId": "OG001", "value": "15.5", "spread": "20.36"}, {"groupId": "OG002", "value": "12.1", "spread": "20.13"}]}]}]}, {"type": "SECONDARY", "title": "Mean Work Productivity Loss Due to Asthma", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS, who were employed", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of productivity loss", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "85"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.56", "spread": "25.589"}, {"groupId": "OG001", "value": "24.44", "spread": "24.689"}, {"groupId": "OG002", "value": "27.29", "spread": "25.802"}]}]}]}, {"type": "SECONDARY", "title": "Mean Productivity Loss Due to Asthma in Classroom", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS, who took classes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of productivity loss", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.92", "spread": "23.765"}, {"groupId": "OG001", "value": "14", "spread": "16.733"}, {"groupId": "OG002", "value": "33.5", "spread": "25.593"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants That Utilized Health Care Resources", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"title": "Hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Emergency department visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "18"}]}]}, {"title": "Unscheduled outpatient visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "83"}]}]}, {"title": "Home visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Telephone calls", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": "Ambulance transports", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Patient and Clinician Assessment of Response to Treatment", "description": "CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL, High-dose ICS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}, {"groupId": "OG002", "value": "248"}]}], "classes": [{"title": "CGIC, Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "97"}]}]}, {"title": "CGIC, Much Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "65"}]}]}, {"title": "CGIC, Very Much Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "CGIC, Total", "categories": [{"measurements": [{"groupId": "OG000", "value": "217"}, {"groupId": "OG001", "value": "190"}, {"groupId": "OG002", "value": "176"}]}]}, {"title": "PGIC, Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "95"}, {"groupId": "OG002", "value": "99"}]}]}, {"title": "PGIC, Much Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "66"}]}]}, {"title": "PGIC, Very Much Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "17"}]}]}, {"title": "PGIC, Total", "categories": [{"measurements": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "182"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks", "seriousNumAffected": 46, "seriousNumAtRisk": 438, "otherNumAffected": 244, "otherNumAtRisk": 438}, {"id": "EG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks", "seriousNumAffected": 41, "seriousNumAtRisk": 428, "otherNumAffected": 232, "otherNumAtRisk": 428}, {"id": "EG002", "title": "Placebo", "description": "Placebo administered subcutaneously", "seriousNumAffected": 61, "seriousNumAtRisk": 440, "otherNumAffected": 264, "otherNumAtRisk": 440}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Aortic valve stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 440}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Gastroduodenitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Rectal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Hepatitis alcoholic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Bacterial infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Bronchitis haemophilus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Cytomegalovirus hepatitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Liver abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 6, "numAffected": 4, "numAtRisk": 440}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 440}]}, {"term": "Pseudomonas bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Pseudomonas infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Anastomotic ulcer", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Toxicity to various agents", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Dupuytren's contracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Epiphysiolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Intervertebral disc disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Jaw cyst", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Spondylolisthesis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Breast cancer female", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Colon neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Gallbladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Thyroid adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 21, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 27, "numAffected": 19, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 38, "numAffected": 23, "numAtRisk": 440}]}, {"term": "Hyperventilation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Nasal turbinate hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Parakeratosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Urticaria papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Aortic stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 440}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}, {"term": "Venous thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 440}]}], "otherEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 16, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 440}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 19, "numAffected": 14, "numAtRisk": 440}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 51, "numAffected": 40, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 54, "numAffected": 45, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 72, "numAffected": 54, "numAtRisk": 440}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 24, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 17, "numAffected": 12, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 27, "numAffected": 25, "numAtRisk": 440}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 132, "numAffected": 90, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 131, "numAffected": 82, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 147, "numAffected": 92, "numAtRisk": 440}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 17, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 440}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 24, "numAffected": 18, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 22, "numAffected": 17, "numAtRisk": 440}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 31, "numAffected": 23, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 30, "numAffected": 21, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 56, "numAffected": 39, "numAtRisk": 440}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 35, "numAffected": 29, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 53, "numAffected": 37, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 53, "numAffected": 42, "numAtRisk": 440}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 16, "numAffected": 14, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 14, "numAffected": 10, "numAtRisk": 440}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 17, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 20, "numAffected": 16, "numAtRisk": 440}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 63, "numAffected": 33, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 65, "numAffected": 34, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 57, "numAffected": 32, "numAtRisk": 440}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 76, "numAffected": 50, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 50, "numAffected": 32, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 96, "numAffected": 52, "numAtRisk": 440}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 18, "numAffected": 14, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 12, "numAffected": 8, "numAtRisk": 440}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 21, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 19, "numAffected": 16, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 28, "numAffected": 24, "numAtRisk": 440}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 12, "numAtRisk": 438}, {"groupId": "EG001", "numEvents": 23, "numAffected": 18, "numAtRisk": 428}, {"groupId": "EG002", "numEvents": 24, "numAffected": 22, "numAtRisk": 440}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Mitchell Goldman, Medical Science Director", "organization": "AstraZeneca", "email": "Mitchell.Goldman@astrazeneca.com", "phone": "+1 301 398 0323"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}